A5045569731- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Urologic and reproductive health conditions
- Atomic and Subatomic Physics Research
- Advanced MRI Techniques and Applications
- Molecular Biology Techniques and Applications
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Estrogen and related hormone effects
- Nutrition, Genetics, and Disease
- Bladder and Urothelial Cancer Treatments
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
University Hospital Ulm
2020-2025
Klinik und Poliklinik für Nuklearmedizin
2021-2024
Abstract Purpose 68 Ga-PSMA-11-PET/CT is increasingly used in early-stage biochemical recurrence of prostate cancer to detect potential lesions for an individualized radiotherapy concept. However, subtle findings especially concerning small local recurrences can still be challenging interpret and are prone variability between different readers. Thus, we analyzed interobserver variability, detection rate, lesion patterns systematically a homogeneous patient population with low-level...
266 Background: We previously established prognostic nomograms of PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria in a large single-center cohort. Now, we reassess the PROMISE (PPP) international multi-center registry study with overall survival follow-up. Methods: included patients histologically proven prostate cancer who underwent at 20 hospitals Germany, Italy, Sweden, Netherlands, Belgium, Slovakia, Austria, United States and...
We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study. included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 2022. Investigator sites were split 2:1 into...
5045 Background: We previously established prognostic two-tier risk nomograms based on PSMA-PET and Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria in a large single-centre cohort. Here, we validate three-tier stratification by PROMISE (PPP2) international multi-centre registry study for prostate cancer survival. Methods: included patients who underwent at 20 hospitals EU, USA or Australia between 2013 2022. was standardized version 2 (V2). Total lesion count,...
Background and Purpose Salvage radiotherapy (SRT) is the main potentially curative treatment option for prostate cancer patients with post-prostatectomy PSA progression. Improved diagnostics by positron emission tomography/computed tomography (PET/CT) can lead to adjustments in procedures (e.g. target volume of radiotherapy, androgen deprivation therapy). We analyzed impact 68 Ga-PSMA-11-PET/CT on early biochemical recurrence (PSA up 0.5 ng/ml). Patients Methods retrospectively 76 after...
PSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled 68Ga 177Lu, survival after treatment 225Ac-PSMA-TO-1/-617 murine model disseminated prostate cancer. also report dosimetry data 177Lu-PSMA-TO1/-617 cancer patients. First, PET images 68Ga-PSMA-TO-1/-617/-11 were acquired on consecutive days three bearing C4-2 xenografts. Second, 50...
Zielsetzung Multiparametric MRI (MRI) plays an essential role to assess prostatic malignancy. PSMA-PET (PET), mainly performed in patients with suspected prostate cancer (PCa) recurrence, might as well be favourable intraprostatic PCa detection. We compared and PET using [F-18]siPSMA-14 histological confirmed evaluate intermodal discrepancies detection biopsy samples reference.
Zielsetzung The acquisition of an attenuation map for each bed position is essential PET/MR examinations to obtain quantitative PET images. Current correction (AC) methods are based on breath-hold acquisitions thus hampering areas that might be affected by respiratory motion such as the upper abdomen. Here, we investigated a free breathing approach correction.
Ziel/Aim In der Primärabklärung bei Verdacht auf ein Prostatakarzinom (PCa) ist die multiparametrische MRT (MRT) etabliert in Detektion signifikanter Tumore, PSMA-PET (PET) wird zunehmend Hoch-Risiko-Konstellation zum Ausschluss einer Fernmetastasierung im Primärstaging angewendet. Ziel dieser Arbeit war es PET und intraindividuell hinsichtlich Tumordetektion mit Biopsie als Referenz zu vergleichen, um Biopsieplanung präzisieren.
Ziel/Aim Die Aufnahme einer MRT-Sequenz zur PET-Schwächungskorrektur (AC) ist für die PET/MR essenziell, diese wird in der Regel Atemanhalt aufgenommen. Insbesondere ältere und pädiatrische PatientInnen können von einem Ansatz mit freier Atemtechnik profitieren. In dieser Arbeit wurde Schwächungskorrektur Atmung untersucht.
Ziel/Aim Die Erfassung der Tumorausdehnung und die exakte lokoregionäre Tumordetektion bei niedrigen biochemischen Rezidiven (BCR) nach radikaler Prostatektomie (RP) Prostatakarzinom (PCa) Patienten (Pat.) sind für eine individuelle Therapieplanung von besonderem Interesse. Das Ziel dieser Studie war Analyse Wertigkeit einer zur [F-18]siPSMA-14-PET/CT ergänzenden PET/mpMRT inklusive DCE (dynamic contrast enhanced) MRT des Beckens Verbesserung lokalen Tumordetektion.
Ziel/Aim To evaluate the predictive and prognostic value of neuroendocrine differentiation (NED) serum biomarkers chromogranin A (CgA) neuron specific enolase (NSE) for treatment response after 2 cycles Lu-177 PSMA (RLT) overall survival (OS) in metastasized castration-resistant prostate cancer (mCRPC).
Ziel/Aim Wir analysierten den neuen PET-Tracer [F-18]siPSMA14 in einem heterogenen Patientenkollektiv zur Überprüfung der Untersuchervariabilität klinischen Routine.